Print page content Print
Increase text size Decrease text size
Text Size
Dog facing camera

ProHeart 12
Safety Information

Safety Profile

Across 6 studies, ProHeart 12 was administered to a wide variety of dogs 12 months of age and older*

Illustration of clipboard with check mark and copy that reads 'Across 5 studies'
  • ProHeart 12 administered at 1x, 3x, and 5x the recommended dose did not result in any systemic adverse effects
  • ProHeart 12 was used with 252 unique concurrent medications in the field study (eg, NSAIDs, antiparasitic agents, and antimicrobials)1

Studies support safety in:

  • Female reproducing dogs and their offspring
  • Male reproducing dogs
  • Ivermectin-sensitive collies
  • Heartworm-positive dogs*

Around the World, Zoetis Has Sold:

Illustration of world

>12 million doses
of ProHeart 12†‡2

>20 million doses
of ProHeart 6†3

Known outside the US as ProHeart SR-12.

Illustration of heart with AEs

Adverse events associated with ProHeart 12 and ProHeart 6 were rare§2,3

Adverse Reactions

The most common adverse events were vomiting, diarrhea, and lethargy. Less commonly mild injection site reactions (warmth, swelling) have been noted in some dogs.1

  • In a field study, ProHeart 12 had a similar adverse events profile to Heartgard® Plus
Large microsphere on adipose tissue

The ProHeart Mode of Action

Learn More

Get Certified Today

If you’re already certified to administer ProHeart 6® (moxidectin), you do not need to recertify for ProHeart 12.

Certify Now

Order ProHeart 12

Already certified? Sign in or register today to order ProHeart 12. It's an easy process that can be done directly online.

Order Online

*Caution should be used when administering a macrocyclic lactone to dogs with high circulating microfilaria counts. PH12 administered at 3x label dose in heartworm-positive dogs had no adverse clinical effects.

Doses sold are calculated using a standard dog weight of 44 lbs and provide an estimate of the number of dogs treated. The actual number of dogs treated can't be determined from sales or adverse drug event data.

§Rare means more than 1 but less than 10 adverse events per 10,000 doses.4 This is a reporting rate, because the total number of dogs treated is unknown. Reporting rates can underestimate the actual number of adverse events, due to underreporting of adverse events.

IMPORTANT SAFETY INFORMATION: Use PROHEART 6 in dogs 6 months of age or older and PROHEART 12 in dogs 12 months of age or older. Do not administer to dogs that are sick, debilitated, underweight, have a history of weight loss, or to those previously found to be hypersensitive to the drug. Hypersensitivity reactions may occur in some dogs when PROHEART is administered alone or with vaccines. Anaphylactic and anaphylactoid reactions can result in death and should be treated immediately with the same measures used to treat hypersensitivity reactions to vaccines and other injectable products. Reported side effects in clinical trials included vomiting, lethargy, diarrhea, anorexia, and hypersensitivity reactions. People should avoid inhalation, contact with eyes, or accidental self-injection. Certification is required before veterinarians and staff administer these products. See full Prescribing Information for PROHEART 6 and PROHEART 12, attached.

References: 1. Study A161C-US-13-330. Data on File. Zoetis Inc. 2. ProHeart 12 Pharmacovigilance Data. Data on file. Zoetis Inc. 3. ProHeart 6 Pharmacovigilance Data. Data on file. Zoetis Inc. 4. Volume 6C: Summary of the Product Characteristics: SPC - Pharmaceuticals 2006. Data on file. Zoetis inc.

Heartgard Plus is a registered trademark of Boehringer Ingelheim.

The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

All trademarks are the property of their respective owners.
©2019 Zoetis Services LLC. All rights reserved. PHT-00016

CONTACT US

1-888-963-8471

We are Mon–Fri, 8am–8pm ET

email to productsupport@zoetisus.comproductsupport@zoetisus.com

This site is intended for U.S. Animal Healthcare Professionals.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2019 Zoetis Services LLC. All rights reserved.